-
Recent Posts
- Merck Provides Update on REVEAL Outcomes Study of Anacetrapib
- New drugs to treat anemia of chronic kidney disease
- FDA Endocrinologic and Metabolic Drugs Advisory Committee recommends approval of dapagliflozin for the treatment of type 2 diabetes in adults
- Combined ACE inhibition and angiotensin receptor blockade shows no advantage over single agent RAS inhibition in patients with diabetic nephropathy: VA-Nephron D study
- FDA Advisory Committee recommends against approval of Tolvaptan for polycystic kidney disease
Recent Comments
Archives
Categories
Meta
Author Archives: admin
The Costs of Clinical Trials and Drug Development
A recent report published in Pharmalot shows that the cost of conducting clinical trials has risen to staggering figures. Across all therapeutic areas, the average cost per patient in phase 1 trials rose from $15,023 in 2008 to 21,882 in … Continue reading
OMONTYS® (peginesatide) recalled due to fatal allergic reactions
On February 23, 2013, Affymax and Takeda announced a voluntary nationwide recall of all lots of Omontys (peginesatide), a peptide mimetic erythropoiesis stimulating agent (ESA), which was approved on March 27, 2012 by the FDA for the treatment of anemia … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment
Targeted therapy with folate-conjugated rapamycin, a promising treatment for PKD
Autosomal dominant polycystic kidney disease(ADPKD) is a common genetic kidney disease caused by mutations in either PKD1 or PKD2 genes, resulting in the presence of multiple cysts that increase in size and lead to a number of complications, including early-onset … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment
Trials and tribulations in kidney disease
On November 3, 2012 at the recent meeting of the American Society of Nephrology-Kidney Week in San Diego, the results of three important clinical trials in nephrology were presented during a special session on High Impact Clinical Studies. The first … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment
Phase 3 Clinical Trial of CKD Drug Bardoxolone Halted on Safety Concerns
Reata Pharmaceuticals announced yesterday (Oct 18, 2012) that it has decided to terminate the phase 3 clinical trial of Bardoxolone methyl [BEACON] for treatment of patients with stage 4 kidney disease and type 2 diabetes. Abbott is co-developing Bardoxolone and … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment
Calcium-Free Phosphate Binders – Review
This article was originally published in abbreviated form at an Spanish on-line journal [http://www.siicsalud.com/dato/dat048/06406023a.htm]. The attached pdf link is the full version, not published previously. The article summarizes the issues related to phosphate retention, excess calcium absorption due to the … Continue reading
Posted in M Loghman-Adham, MD
Leave a comment
Nephrotoxicity During Drug Development
A new review of this subject entitled Detection and Management of Nephrotoxicity during Drug Development has been recently published in Expert Opinion on Drug Safety. The article has been available ahead of print on-line since May 22, 2012. The authors are … Continue reading
ALTITUTE trial of aliskiren on top of ACE or ARB discontinued on DSMB recommendation
Dec 20, 2011 Shelley Wood from heartwire Basel, Switzerland – An increase in adverse events and no apparent benefits among patients randomized to aliskiren (Rasilez/Tekturna, Novartis) in the ALTITUDE trial has prompted the data safety and monitoring board (DSMB) for … Continue reading
The FNIH Biomarkers Consortium Launches Project to Improve Diagnosis of Kidney Injury
Bethesda, MD (November 1, 2011) – The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announced today the launch of a two-year clinical study aiming to advance the acceptance of new biomarkers designed to detect drug-induced kidney injury … Continue reading
STAT3 as a possible new drug target for polycystic kidney disease
Two discoveries at UC Santa Barbara point to potential new drug therapies for patients with kidney disease. The findings are published in this week’s issue of the Proceedings of the National Academy of Sciences. Over 600,000 people in the U.S., … Continue reading